Genome editing technologies hold great promise for numerous applications including the
understanding of cellular and disease mechanisms and the development of gene and …

Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro,
with or without genetic modification, is a rapidly growing area of drug development, even …

Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …

Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, often fatal immune
deficiency characterized by severe systemic hyperinflammation. Although allogeneic bone …

Ex vivo modification of T cells with exogenous cargo is a common prerequisite for the
development of T cell therapies, such as chimeric antigen receptor therapy. Despite the …

Background CRISPR/Cas9 system to treat human-related diseases has achieved significant
results and, even if its potential application in cancer research is improving, the application …

The use of a patient's own immune or tumor cells, manipulated ex vivo, enables Ag-or
patient-specific immunotherapy. Despite some clinical successes, there remain significant …

Target cancer therapy has been developed for clinical cancer treatment based on the
discovery of CRISPR (clustered regularly interspaced short palindromic repeat)-Cas system …

Chimeric antigen receptor (CAR)-redirected immune cells hold significant therapeutic
potential for oncology, autoimmune diseases, transplant medicine, and infections. All …

The rapid progress of nanotechnology has led to use different nanomaterials for biomedical
applications. Among them, graphene-encapsulated magnetic nanoparticles (GEMNS) are …